This study investigates the use of an investigational medication for the first-line treatment of advanced or metastatic urothelial cancer. Urothelial cancer affects the bladder and other parts of the urinary tract. This study focuses on participants who cannot undergo surgery or are ineligible for cisplatin-based therapy, a common cancer treatment.
Participants will receive the investigational medication and their progress will be monitored by the study team. The study will involve regular assessments to evaluate the effectiveness and safety of the treatment.
- Who can participate: Participants with advanced or metastatic urothelial cancer who cannot have surgery or cisplatin-based therapy may be eligible.
- Study details: Participants will receive an investigational medication and be monitored by the study team. Regular assessments will be conducted to check the treatment's effectiveness and safety.
